Serotonin antagonism in panic disorder: an open trial with ritanserin.
Eleven patients with panic disorder were administered ritanserin, a post-synaptic serotonin S2 antagonist, during a 4 week period at a daily dose of 10-20 mg. The treatment resulted in a decrease in the number of panic attacks, and a diminution of agoraphobic avoidance. The possible practical and theoretical signification of these findings is discussed.
Griez
E
E
State University of Limburg, Department of Clinical Psychiatry, Maastricht, The Netherland.
Pols
H
H
Lousberg
H
H
D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy; D004924:Escape Reaction / Q000187:drug effects; D005239:Fear / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D010200:Panic / Q000187:drug effects*; D010698:Phobic Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D016713:Ritanserin; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D010880:Piperidines; D012702:Serotonin Antagonists; D016713:Ritanserin